Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transcranial magnetic stimulation for depression.

Philip B Mitchell1, Colleen K Loo

  • 1School of Psychiatry, University of New South Wales, Black Dog Institute, Prince of Wales Hospital, Randwick, Australia. phil.mitchell@unsw.edu.au

The Australian and New Zealand Journal of Psychiatry
|May 11, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness and safety of repeat dose subcutaneous ketamine for treatment-resistant depression, and the impact of prior ketamine treatment: open label extension of the KADS study.

The British journal of psychiatry : the journal of mental science·2026
Same author

Gordon Parker's bipolar disorder research.

Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists·2026
Same author

Brain Morphology Mediators of the Association of Childhood Trauma With Bipolar Disorder: An International ENIGMA Bipolar Disorder Working Group Study.

JAMA psychiatry·2026
Same author

Improving access to novel treatments for treatment-resistant depression: The potential role of specialist clinics in Australia.

The Australian and New Zealand journal of psychiatry·2026
Same author

White matter microstructure in relatives of people with schizophrenia or bipolar disorder: an ENIGMA meta-analysis.

Molecular psychiatry·2026
Same author

The American Society of Clinical Psychopharmacology task force consensus statement on the deprescribing of stimulant medications in adults with ADHD<sup>✰</sup>.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026

Repetitive transcranial magnetic stimulation (rTMS) shows statistical efficacy for depression treatment, but clinical benefits are minimal. Further research is needed to determine optimal parameters and widespread clinical approval for this neuromodulation technique.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Medical Technology

Background:

  • Repetitive transcranial magnetic stimulation (rTMS) is an emerging non-invasive neuromodulation technique.
  • Its application in treating major depressive disorder (MDD) has been investigated through numerous clinical trials.

Purpose of the Study:

  • To systematically review the existing literature on the efficacy, safety, and response predictors of rTMS for depression.
  • To synthesize findings from sham-controlled studies and meta-analyses.

Main Methods:

  • A descriptive review of over 25 published sham-controlled rTMS studies in depression.
  • Analysis focused on meta-analyses and individual trial reports, examining stimulation parameters and clinical features.

Main Results:

Related Experiment Videos

  • Clear statistical superiority of left-prefrontal high-frequency rTMS over sham therapy was observed.
  • Clinical benefits were generally marginal, with uncertainty regarding optimal stimulation parameters.
  • Predictors of greater response included younger age, absence of antidepressant refractoriness, and no psychotic features.

Conclusions:

  • Current evidence confirms the statistical efficacy of rTMS for depression but highlights insubstantial clinical benefit.
  • Large multicenter studies are ongoing to assess regulatory approval potential.
  • Further clarification is required on optimal rTMS administration parameters for effective depression treatment.